Promedior logo — Pioneering advanced therapies to heal fibrotic and inflammat...

Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source, enhancing precision and minimizing systemic risks

Founded 2006 Venture round Total: $63.00M Biopharma, Biotechnology +2

General Information

Company Name Promedior
Founded Year 2006
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Promedior. To contact Promedior, visit promedior.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Promedior compare?

A PDF of Promedior and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Promedior soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Promedior

Promedior is a biopharmaceutical startup founded in 2006, focused on developing innovative treatments for inflammatory and fibrotic diseases. The company's unique drug discovery platform targets monocyte-derived cell populations critical in fibrotic, inflammatory, and autoimmune conditions, directly addressing the root cause of improper immune responses and minimizing widespread side effects found in current treatments. Promedior's medications aim to treat severe fibrotic and inflammatory conditions affecting vital organs such as the eye, lung, and kidney, including glaucoma, age-related macular degeneration, diabetic retinopathy, and pulmonary fibrosis. In January 2019, Promedior secured a Venture Round investment from Sofinnova Investments, signaling confidence in its pioneering approach to healing fibrotic and inflammatory diseases. With a focus on enhancing precision and minimizing systemic risks, Promedior is poised to make a significant impact in the biopharma, biotechnology, and health care industries.

Business keywords: biopharmaceutical, drug discovery, therapeutics, fibrotic diseases, inflammatory diseases, clinical-stage, monocyte-derived cell populations, immunotherapy, tissue healing, precision medicine, autoimmune conditions, eye diseases, lung diseases, kidney diseases, novel therapeutics

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round Undisclosed 1
Sofinnova Investments
01 Jan 2019
Series D $3.00M 7
Easton Capital, Polaris Partners +5
15 Oct 2012
Series D $21.50M 6
Easton Capital, Polaris Partners +4
07 Mar 2012
Debt Financing $6.50M -
17 Oct 2011
Series C $12.00M 1
Forbion
17 Mar 2010
Series B $6.00M -
25 Feb 2009
Series A $14.00M 5
Easton Capital, Polaris Partners +3
24 May 2006

Promedior Alternatives & Competitors

View All Alternatives
Promedior vs

Developing innovative precision therapies for the treatment of inflammatory and fibrotic diseases

Grant
10 employees
Biotechnology, Health and Wellness
Promedior vs

Building a leading biotech company focused in severe autoimmune diseases.

Post-IPO Equity
124 employees
Biopharma, Biotechnology
Promedior vs
AnaptysBio
AnaptysBio United States

Transforming patient health by delivering innovative immunology therapeutics.

IPO
144 employees
Biotechnology, Health Care

FAQ About Promedior

Pioneering advanced therapies to heal fibrotic and inflammatory diseases at their source, enhancing precision and minimizing systemic risks
Promedior was founded in 2006.
Promedior operates in Biopharma, Biotechnology, Health Care and Health and Wellness. Its work centres on biopharmaceutical, drug discovery, therapeutics and fibrotic diseases.
Promedior has completed 7 funding rounds, raising a total of $63.00M. The latest funding stage is Venture round.
Top alternatives and competitors to Promedior include Certa Therapeutics, Dianthus Therapeutics, Inc., AnaptysBio, Flame Biosciences, Angion. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Promedior and Certa Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Promedior, https://bouncewatch.com/company/promedior, updated 28 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes